Sacubitril-Valsartan in a routine community population: attention to volume status critical to achieving target dose.
Rebabonye B PharithiMaria Ferre-VallverduAlan S MaiselEoin O'ConnellMyra WalsheClaire SweeneyJames BartonKathrine McDonaldDaniel O'HareChris WatsonJoe GallagherMark LedwidgeKenneth McDonaldPublished in: ESC heart failure (2020)
Sacubitril-valsartan was well tolerated. Achievement of TD was possible in the majority of the cohort and was linked to response metrics. Reduction in diuretic was required in a large percentage of the population and was the strongest predictor of attaining TD. Therefore, careful clinical attention to volume status assessment is essential to maximising the benefits of sacubitril-valsartan.